Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NT5E | P21589 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31275351 | 1.00 | HTT (0.50) | HTTKMT2AKDM4ECA1CA2 | |
| Bromide SCHEMBL7392827 | 0.98 | HTT (0.48) | HTTKMT2AKDM4ECA1CA2 | |
| SCHEMBL29045347 | 0.98 | HTT (0.48) | HTTKMT2AKDM4ECA1CA2 | |
| SCHEMBL29267304 | 0.81 | HTT (0.50) | HTTKMT2AKDM4ECA1CA2 | |
| SCHEMBL28645824 | 0.79 | HTT (0.48) | HTTKMT2AKDM4ECA1CA2 | |
| SCHEMBL10571476 | 0.78 | ALDH1A1 (0.50) | KDM4ECA1CA2CA9ALDH1A1 | |
| SCHEMBL7392823 | 0.78 | HTT (0.47) | HTTKMT2AKDM4ECA1CA2 | |
| SCHEMBL2650456 | 0.77 | ALDH1A1 (0.59) | HTTKMT2AALDH1A1GAAMAPT | |
| SCHEMBL5623766 | 0.77 | NOS3 (0.50) | KMT2AKDM4EALDH1A1TSHRNT5E | |
| SCHEMBL27903839 | 0.77 | KDM4E (0.48) | KDM4ECA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119114152-A | Free radical generating catalyst, method for producing free radical, method for producing oxidation reaction product, pharmaceutical agent, and agricultural and livestock pharmaceutical agent | 株式会社ACENET | 2024-12-13 | — | — | CN | disclosed |
| CN-110769931-B | Free radical generating catalyst, method for producing free radical, method for producing oxidation reaction product, pharmaceutical agent, and agricultural and livestock pharmaceutical agent | 株式会社ACENET | 2024-09-17 | — | — | CN | disclosed |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | ACENET INC. (JP) | 2024-01-04 | — | — | US | disclosed |
| WO-2023190598-A1 | COMPOSITION | アース製薬株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230263710-A1 | ORAL CARE AGENT | OSAKA UNIVERSITY (JP) | 2023-08-24 | — | — | US | disclosed |
| EP-4230042-A1 | ANTIPATHOGENIC DRUG, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN PROCESSING DEVICE, METHOD FOR PRODUCING ANTIPATHOGENIC DRUG, ANTIBACTERIAL METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN PROCESSING METHOD | Acenet Inc. (JP) | 2023-08-23 | — | — | EP | disclosed |
| US-20230181628-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | OSAKA UNIVERSITY (JP) | 2023-06-15 | — | — | US | disclosed |
| CN-116157109-A | Oral pharmaceutical preparation | 国立大学法人大阪大学 | 2023-05-23 | — | — | CN | disclosed |
| EP-4147703-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | OSAKA UNIVERSITY (JP) | 2023-03-15 | — | — | EP | disclosed |
| CN-115666593-A | Therapeutic agent for epithelial cancer | 国立大学法人大阪大学 | 2023-01-31 | — | — | CN | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| CN-1229349-C | Pyridine-3-carboxylic acid derivative | PFIZER (US) | 2005-11-30 | — | — | CN | disclosed |
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| CN-1495169-A | Pyridine-3-carboxylic acid derivative | — | 2004-05-12 | — | — | CN | disclosed |
| EP-1371647-A2 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1073658-B1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1285658-A2 | Treatments for female sexual dysfunction | Pfizer Productors Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| US-6458951-B2 | FOR TREATMENT OF MALE ERECTILE DYSFUNCTION, FEMALE SEXUAL DYSFUNCTION | PFIZER INC | 2002-10-01 | — | — | US | disclosed |
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | HTT 4170/4885KMT2A 4533/4885KDM4E 1840/4885 |
| US-20230263710-A1 | ORAL CARE AGENT | TAS2R39, TAS2R40, TAS2R45 | HTT 2471/4885KMT2A 476/4885KDM4E 1296/4885 |
| US-20230181628-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | EPCAM, EGFR, MUC1 | HTT 4651/4885KMT2A 2505/4885KDM4E 3793/4885 |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | EIF2AK2, HAO2, ZC3HAV1 | HTT 94/4885KMT2A 2886/4885KDM4E 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.